Recent Updates
Recently added Catalysts

RYZ801

Phase 1

HCC | Small molecule | Other |Bristol-Myers Squibb Company|Last Updated: May 24, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment70
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06726161Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCCPHASE1 RECRUITING 70 — — Nov 1, 2024Jan 1, 2031May 24, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
RYZ811DIAGNOSTIC_TESTGa-68
RYZ801DRUGAc-225
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06726161studyFirstPostDate: changed